NCT04662528View on ClinicalTrials.gov

Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ≥500 mg/dL and <2000 mg/dL

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2021

Primary Completion Date

August 31, 2022

Study Completion Date

October 31, 2022

Conditions
Severe Hypertriglyceridemia
Interventions
DRUG

Placebo

4 x 1g capsules/day

DRUG

MAT9001 (omega-3 pentaenoic acid)

4 x 1g capsules/day

Sponsors

Collaborators (1)

Covance
All Listed Sponsors
collaborator

Covance

INDUSTRY

lead

Matinas Biopharma, Inc

INDUSTRY